Press Release

August 11, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Sub: Press Release Ref.: Disclosure under regulation 30 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Pursuant to the provisions of regulation 30 of the Listing Regulations, please find enclosed the press release dated August 11, 2026, to be published in the newspapers relating to unaudited financial results for the quarter ended on June 30, 2026. Please find the same in order. Yours faithfully, For, ZYDUS LIFESCIENCES LIMITED DHAVAL N. SONI COMPANY SECRETARY AND COMPLIANCE OFFICER MEMBERSHIP NO. FCS7063 Encl.: As above Zydus Lifesciences Limited Financial Performance for Q1 FY2 7 11th August , 202 6, Ahmedabad, India Q1 FY27 Key Financial Highlights Q1 FY2 7 Highlights • Revenue from operations at Rs. 80 ,170 mn, up 22% over last year . • R&D investment s for the quarter stood at Rs. 6,424 mn ( 8% of revenues). • EBITDA for the quarter was Rs. 19,294 mn, down 8% y -o-y. EBITDA margin for the quarter stood at 24.1%. • Net Profit for the quarter was Rs. 9,398 mn, down 36% y -o-y. • Capex (organic) for the quarter was Rs. 5,852 mn. • Net Debt to Equity ratio as on 30th June 202 6 was 0. 22x while Net Debt to EBITDA stood at 0. 70x at the end of June 202 6. Q1 FY27 Consolidated Financial Results Q1 Q1 % Gr. Q4 % Gr. Rs. Mn FY2 7 FY2 6 YoY FY2 6 QoQ Revenue from operations 80,170 65,737 22.0% 75,870 5.7% EBITDA 19,294 20,885 -7.6% 25,544 -24.5% EBITDA margin (%) 24.1% 31.8% 33.7% PBT 13,066 19,206 -32.0% 16,597 -21.3% Net Profit 9,398 14,668 -35.9% 12,725 -26.1% FY27 is off to a strong, profitable start. We continue advancing into an innovation -led, patient-centric organization. Our branded portfolio now exceeds 55% of revenues. Notably, the share of branded sales in the US reached 11% and will continue to expand with the upcoming Saroglitazar launch. Backed by diverse manufacturing and robust quality systems, we will further strengthen our core businesses and expand our market share. Driven by execution rigor and acquisition synergies, we are well -positioned for o ur next growth phase. Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited Q1 FY27 Business -wise Sales Performance (Consolidated) Q1 Q1 % Gr. Q4 % Gr. Rs. Mn FY2 7 FY2 6 YoY FY2 6 QoQ Pharma Business 60,900 56,101 8.6% 56,436 7.9% India Formulations 18,158 15,192 19.5% 17,528 3.6% North America Formulations 30,979 31,817 -2.6% 29,523 4.9% IM Formulations 9,735 7,265 34.0% 8,041 21.1% APIs 1,804 1,575 14.5% 1,219 48.0% Alliances & Others 224 252 -11.1% 125 79.2% Consumer Wellness 14,292 8,549 67.2% 14,633 -2.3% MedTech 2,828 20 3,275 -13.6% Consolidated Revenues 78,020 64,670 20.6% 74,344 4.9% Q1 FY2 7 Consolidated business mix Q1 FY2 7 Pharma business mix Medtech North America Formulations Consumer Wellness Pharma Business 40% IM Formulations 78% 12% India Formulations APIs & Others Q1 FY2 7 Business Updates Pharma Business India Formulations business • Registered revenues of Rs. 18,158 mn, up 20% y -o-y. The business accounted for 23% of consolidated revenues. • The business has consistently outperformed IPM growth over the last 3 financial years . • Growth during the quarter was broad based as the business grew faster than the market in super -specialty , chronic and acute segments. • In terms of therap eutic performance , outpaced IPM growth in key therapies of Cardiology, Diabetology, Gynaecology, Anti -infectives, Pain Management and in super specialty areas of Oncology and Nephrology . • Ranking improved in key therapies of Cardiology, Diabetology and Pain Management while on the super specialty front, retain ed leadership position in Oncology segment. • Large innovative brands led by Lipaglyn ® continue to strengthen their market standing and improve their rankings quarter after quarter, underscoring the impact of innovation on improved patient outcomes. • Share of chronic and sub chronic portfolio has increased consistently over last several years and stood at 54.2%, an improvement of 360 bps over the last 4 years (Source: AWACS MAT June 2026 data). North America formulations business • Registered revenues of Rs. 30,979 mn, down 3% y -o-y and up 5% q-o-q. The business accounted for 40% of consolidated revenues. • In constant currency terms, the business registered revenues of US$ 327 mn. • US base business continued to gain market share driven by sustained volume expansion supplemented by new products launches. • In the US generics space, filed 5 ANDAs , received approval for 9 ANDAs (including 4 tentative approvals ) and l aunched 11 new products during the quarter. • On the US specialty front , o Launched NUFYMCO ™ (Ranibizumab) injection, the company’s first biosimilar in the US market. o Completed the acquisition of Assertio Holdings, significantly strengthen ing presence in the US specialty space . • In Canada, received 2 ANDS approvals and launched 2 new products during the quarter. International Markets formulations business • Registered revenues of Rs. 9,735 mn, up 34% y-o-y. The business accounted for 12% of consolidated revenues. • Growth was led by strong demand -driven performance across markets and supported by focused execution. API business • Registered revenues of Rs. 1,804 mn, up 15% y -o-y. The business accounted for 2% of consolidated revenues. Alliances & Others • Registered revenues of Rs. 224 mn, down 11% y -o-y. The business accounted for 0.3% of consolidated revenues. Consumer Wellness business • Registered revenues of Rs. 14,292 mn, up 6 7% y -o-y. The business accounted for 18% of consolidated revenues. • Domestic business grew 5% y-o-y. Skin & hair care brands and food & nutrition brands registered 3 5% and 16% y-o-y growth respectively . Seasonal brands , however, de-grew primarily due to the softer summer season . • International business, including the Comfort Click business, delivered 25% growth on a like -to-like basis . MedTech business • Registered revenues of Rs. 2,828 mn. The business accounted for 4% of consolidated revenues. • The company is investing in enhancing its capabilities in focused therapies which offer long -term growth potential to create differentiated value. Updates on Operations and Compliance • Injectable manufacturing facility at Zydus Biotech Park received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification following a GMP surveillance inspection conducted in April -May 2026. Updates on Innovation Pipeline NCE Research • The USFDA granted priority review to the New drug Application (NDA) of Saroglitazar Magnesium for the treatment of Primary Biliary Cholangitis (PBC) . • Received regulatory approval in India to initiate Phase III clinical trials of Desidustat in patients with sickle cell disease. Biotech R&D • Initiated Phase III clinical trials in India for the second biosimilar antibody drug conjugate. Vaccines R&D • Completed Phase II clinical trials of bivalent Typhoid Conjugate vaccine and initiated Phase I clinical trials of Chikungunya vaccine in India. • On the global development front, submitted the dossier of Measles and Rubella (MR) vaccine to World Health Organization (WHO). The dossier has been accepted for review. Other Updates • Entered into a joint venture agreement with Sunshine Healthcare Lanka Limited to establish a pharmaceutical manufacturing facility in Sri Lanka to strengthen local production and reduce import dependence for the country. Q1 FY2 7 Earnings Call Details The Company will host its post results earnings call at 4:00 p.m. IST on 11th August , 202 6 during which the leadership team will discuss the financial performance and address questions from the participants . A transcript of the conference call will be available at th [Showing first 8,000 characters — download PDF for full document]